Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help ...

Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, ...

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported ...

After seeing promising results in preclinical studies, the firm hopes to begin Phase I trials shortly after getting IND clearance.